PharmiWeb.com - Global Pharma News & Resources
04-May-2021

Radiodermatitis Market Size 2021 Emerging Trends, Growing At A CAGR of 3.9%, Development Status, Future Demands, Market Potential, Regional Overview and SWOT Analysis till 2027

SEATTLE, May 04, 2021, (PHARMIWEB) —

Overview:

Acute and chronic radiodermatitis are the two forms of radiodermatitis. The acute condition progresses within 90 days after radiation treatment, while the chronic condition develops between 15 days and 10 years or more after the initiation of radiation therapy. Radiodermatitis is treated and controlled with topical drugs, oral medications, and dressings.

The global radiodermatitis market is priced at US$ 360.5 million and is projected to rise to US$ 472.8 million by the end of 2027.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3881

Drivers:       

During the forecast period, the global radiodermatitis market is expected to rise due to the high risk of recurrent radiodermatitis following fluoroscopically driven interventions. For instance, According to a report published in the Journal of Vascular and Interventional Radiology in May 2019, 8.8% of patients who underwent fluoroscopically supervised procedures developed chronic radiodermatitis.

Opportunities:

The lack of a definitive/standard cure provides an enticing prospect for a breakthrough, creating lucrative development prospects for the companies operating in the global radiodermatitis market. Topical agents such as water-based moisturising creams or lotions, topical steroids, anti-inflammatory emulsions, and wound dressings are often used to treat radiation dermatitis symptoms. Also with these choices, there is currently no proven reliable routine procedure for the prevention of radiation-induced dermatitis. This opens up a significant window of potential for the advancement of a game-changing procedure that can be called routine care that is successful in the treatment of radiation-induced skin injury.

Restraints:

Growth of the global radiodermatitis market is expected to be hindered by the new regulatory climate. Clinical trials and regulatory approval are expected for treatment drugs for radiation dermatitis. Conducting trials and obtaining clearance for new technologies is a time-consuming procedure that often necessitates a significant financial commitment.  Certain studies pertaining to this market’s termination or ineffectiveness in obtaining a standard treatment could serve as a deterrent for new entrants, restricting the market’s growth.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3881

Market Trends:

Mepilex Lite (Mölnlycke Health Care, Sweden) is a Swedish silicon-foam skin dressing that is used to treat burns and slow-healing wounds in New Zealand. The use of a silver-leaf nylon dressing has been shown to have antimicrobial efficacy and to improve healing of burns and skin grafts. Radiodermatitis may also be treated with non-adherent dressings such as silicone dressings and no-sting barrier film dressings.

In the market, e-commerce is a big distribution platform. Cavilon no sting barrier video, for example, is available for purchase on 3M’s official website as well as distribution websites like Amazon.  Key players in this industry with big products available online include RadX, Stratpharma, Molnlycke Health Insurance, Medline Industries, and Advancis Medical.

Competitive Landscape:   

Key companies contributing in the global radiodermatitis market are Intermed Pharmaceuticals, ConvaTec Group PLC, Smith & Nephew Plc, BMG Pharma S.r.l., Jay Pharma, Kannalife, Inc., Acelity, Inc. (3M), Stratpharma AG, Integra LifeSciences Holdings Corporation (DermaSciences Inc.), and Molnlycke Health Care.

Key Developments:

ConvaTec Group Plc agreed to buy the assets of Southlake Medical Supplies, Inc., a U.S.-based independent distributor of catheter-related supplies, in September 2019.

Arkis Biosciences Inc., a privately owned firm that sells a range of neurosurgical products, was purchased by Integra LifeSciences Holdings Corporation in July 2019.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/3881

Detailed Segmentation

  • Global Radiodermatitis Market, By Product Type:
    • Topical Agents
      • Corticosteroids
      • Hydrophilic Creams
      • Others
    • Oral Medication
      • Corticosteroids
      • Other (Analgesic & Anti-Inflammatory)
    • Dressings
      • Hydrogel
      • Hydrocolloid
      • No Sting Barrier Film
      • Honey Impregnated Dressing
      • Silicone coated Dressing
      • Others
  • Global Radiodermatitis Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/radiodermatitis-market-3149

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. Shah
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 04-May-2021